Greg Kunst joins Aurion Biotech with deep and varied experience in ophthalmic medical devices, drug delivery systems, diagnostics, biotechnology, and pharmaceutical products. His expertise spans global corporate development, strategy, health policy, marketing, commercialization, business development, market access and medical affairs.
Before Aurion Biotech, Greg spent 6 years at Glaukos Corporation (NYSE: GKOS) in numerous roles of increasing responsibility, most recently as vice president of global marketing, where he led the global marketing, market access, reimbursement, health economics and outcomes research, government affairs, and business development teams. Before Glaukos, Greg worked at Alcon, a Novartis company, as global franchise director over the Alcon glaucoma surgery and retina pharmaceutical businesses. Before joining Alcon, Greg worked at Kinetic Concepts, Inc. (Acelity Inc.) as the global head of market access. Greg is a member of the steering committee for the Gavin Herbert Eye Institute at the University of California, Irvine, and a board member of Pr3vent.
Greg received an MBA from Vanderbilt University and a BS in Economics from Brigham Young University.
FIRM PROFILE
With offices in Seattle, Cambridge and Tokyo, Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech. The CompanyÕs first candidate is for the treatment of corneal edema secondary to corneal endothelial disease, and is the first off-the-shelf, clinically validated cell therapy for corneal care, having received regulatory approval in Japan. The Company is preparing for clinical trials in the U.S. Privately held, Aurion Biotech is backed by leading investors that include Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures.
